← Leaderboards
Samy Lamouille
Acomhal Research, Inc.
$1,053,493
Attributed
$1,482,109
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $414.5K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,482,109 · 4
By mechanism
R21$857,232 · 2
R41$624,877 · 2
Top collaborators
- Stefanie Robel2 shared
- James D Weger1 shared
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroIn VivoMediatingPeptidesMouse ModelCellsMicroscopyFoxp3 GeneResolutionPreventGap JunctionsConnexin 43PeptidomimeticsNeoplastic CellNovel Therapeutic InterventionCell CommunicationMolecular TargetOpticsBiochemistryLinkAffectLaboratoriesCancer CellMalignant Neoplasms
Grant awards (5)
Creating an improved oncolytic virus through directed evolution and virus-driven expression of a cancer-targeting peptid$414,482
R21 · FY2025 · AI
Inhibition of breast cancer cell metastases using a connexin43 mimetic peptide$399,878
R41 · FY2020 · CA · contact PI
Targeting Connexin43 in post-traumatic epilepsy$241,500
R21 · FY2019 · NS · contact PI
Targeting Connexin43 in post-traumatic epilepsy$201,250
R21 · FY2018 · NS · contact PI
Therapeutic disruption of Connexin43-mediated microtubule regulation to target glioblastoma cancer stem cells$224,999
R41 · FY2017 · CA · contact PI